Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyMedical Mutual - Ohio SIBO Coverage Update | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentmedical mutual - ohioPolicy AHS - G2056

    Diagnosis of Idiopathic Environmental Intolerance

    Customize your policy alerts

    Sign up for medical mutual - ohio Policy AHS - G2056 alerts

    Get alerted when Policy AHS - G2056 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage stance for tests and evaluations used to diagnose idiopathic environmental intolerance (IEI, formerly multiple chemical sensitivity) and related proprietary laboratory panels; applies to Medical Mutual - Ohio members and providers seeking coverage determinations.

    Policy Summary
    Payermedical mutual - ohio
    PolicyDiagnosis of Idiopathic Environmental Intolerance
    Policy CodePolicy AHS - G2056
    Change TypeClarified coverage for breath testingadministrative code updates
    Effective DateJun 1, 2026
    Last ReviewDec 3, 2025
    Next Review DateDec 3, 2025
    Key ActionDocument suspected bacterial overgrowth (eg, SIBO) and support breath hydrogen/methane testing with clinical documentation when ordering CPT 91065.
    SourceLink
    POLICY UPDATE CHANGES

    CC7 edited for clarity and consistency with enforcement, as breath hydrogen/methane testing is allowed under certain circumstances.

    CC2 and CC3 replaced 'In all circumstances' with 'For asymptomatic individuals and/or during general encounters without abnormal findings,' for clarity of enforcement.

    Former Section IV. Reimbursement Policy was removed.

    Revised code description for CPT code 83015, 83018 (effective date 1/1/2026).

    All laboratory tests for IEIlisted as not meeting coverage criteria
    SIBO breath testingexplicitly noted as meeting coverage criteria for bacterial overgrowth
    Proprietary panels (e.g., Genova)examples of tests discussed
    No FDA-cleared testsFDA/LDT statement
    20+example CPT/HCPCS codes listed

    Coverage Criteria

    Not Medically Necessary for Diagnosis of IEI

    Tests and panels intended to confirm IEI are not covered.

    Primary exclusion

    • Examples: profiling for volatile solvents, organic acids, organophosphates, phthalates, parabens, chlorinated pesticides (DDE/DDT), metals testing in blood/urine/cerebrospinal fluid/fingernails/hair, micronutrient and intracellular nutrient panels, oxidative stress/detoxification/methylation testing, lipoic acid/CoQ10 panels, organic acid panels, food sensitivity panels when used to diagnose IEI, and proprietary multi-analyte panels (e.g., Genova Organix, NutrEval, SpectraCell Micronutrient, Vibrant Wellness, Metabolomix+)

      Document lists numerous specific specimen types and proprietary panels as not meeting coverage criteria

    Guideline-based testing recommendations

    Guideline recommendations relevant to testing for SIBO and carbohydrate maldigestion

    North American Expert Consensus recommendations:
    Policy Summary
    Payermedical mutual - ohio
    PolicyDiagnosis of Idiopathic Environmental Intolerance
    Policy CodePolicy AHS - G2056
    Change TypeClarified coverage for breath testingadministrative code updates
    Effective DateJun 1, 2026
    Last ReviewDec 3, 2025
    Next Review DateDec 3, 2025
    Key ActionDocument suspected bacterial overgrowth (eg, SIBO) and support breath hydrogen/methane testing with clinical documentation when ordering CPT 91065.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and DocumentationBackgroundDefinitionsReferences and Revision History
    Suggest breath testing for SIBO and assessment of antibiotic-responsive microbial colonization; recommend evaluating methane excretion when associated with constipation; recommend fructose and lactose breath tests be performed for at least 3 hours and that bacterial overgrowth be ruled out before performing lactose or fructose testing
    quality ratings vary (Low-Moderate)

    Recommendations are guideline suggestions, not explicit payer coverage rules.

    ACG recommendations: Suggest use of glucose or lactulose hydrogen breath testing for SIBO in IBS, motility disorders, prior luminal surgery, and symptomatic patients; suggest testing for methane using glucose or lactulose breath tests to diagnose methane-producing overgrowth in constipated symptomatic patients (conditional/weak recommendations)very low evidence

    Guidance emphasizes conditional recommendations.

    Covered diagnostic testing (excerpt)

    Coverage includes targeted diagnostic testing when criteria are met; breath hydrogen/methane testing is covered for suspected bacterial overgrowth.

    Breath testing for bacterial overgrowth (e.g., SIBO): The use of a breath hydrogen and/or breath methane test to assess or diagnose bacterial overgrowth, including but not limited to SIBO, MEETS COVERAGE CRITERIA.N/A

    Aligns with North American Consensus and referenced guideline literature for breath testing.

    The policy explicitly states that laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance (IEI) do not meet coverage criteria. This includes testing of blood, saliva, serum, plasma, urine, stool, hair, fingernails, and cerebrospinal fluid when performed specifically to diagnose IEI, and profiling for volatile solvents, organic acids, organophosphates, phthalates, parabens, and chlorinated pesticides (e.g., DDE/DDT) in asymptomatic individuals or during general encounters without abnormal findings. These specimen types and analyte profiles are considered not medically necessary for diagnosis of IEI and are subject to denial when billed for that purpose.

    Several prominent professional societies have expressed skepticism about IEI/MCS and have discouraged nonvalidated testing approaches. The American Medical Association (AMA) stated that multiple chemical sensitivity should not be recognized as a syndrome until reproducible, well-controlled studies are available. The American Academy of Allergy, Asthma and Immunology (AAAAI) has advised that many nonvalidated immune-based tests used to suggest an immunologic basis for IEI are expensive and not useful, and should be discouraged. The American College of Occupational and Environmental Medicine (ACOEM) likewise found no consistent physical findings or laboratory abnormalities to support routine testing for IEI, and the French ANSES appraisal did not recommend specific testing methods for electromagnetic hypersensitivity, suggesting psychological assessment when indicated.

    The policy revision history notes that the previous Section IV. Reimbursement Policy was removed. The removal was made because that section relied on industry-standard unit restrictions rather than science-driven limits and was creating confusion; enforcement will instead rely on the coverage criteria described elsewhere in this policy.

    The policy enumerates numerous proprietary multi-analyte panels and broad analyte testing that have been marketed for IEI evaluation but lack evidence to support their use for diagnosis. Examples include Genova Diagnostics panels (Organix Comprehensive Profile, NutrEval, GI Effects Profile, SIBO Profile), SpectraCell Micronutrient and antioxidant/function panels, Metabolomix+, Life Extension nutrient panels, and Vibrant Wellness intracellular/extracellular nutrient testing. The document indicates these types of proprietary panels and large-scale analyte profiles are not appropriate to confirm IEI.

    Professional statements cited in the policy discourage the use of many nonvalidated tests proposed for IEI/MCS. The AAAAI position specifically characterizes many such immune-based tests as expensive and not useful; ACOEM and the AMA have raised similar concerns about lack of consistent laboratory abnormalities to support routine diagnostic testing. ANSES likewise found no conclusive evidence to support specific testing for electromagnetic hypersensitivity, recommending psychological evaluation where appropriate. Collectively these statements caution providers against ordering tests that lack established clinical validity and utility for IEI.

    The policy cites consensus documents and systematic reviews that do not support indiscriminate testing for IEI. References include the 1999 international consensus on multiple chemical sensitivity and recent reviews of SIBO and breath testing literature. The revision history reiterates that literature review did not necessitate changes to coverage criteria and supports selective, guideline-aligned use of testing (for example, breath hydrogen/methane testing for suspected bacterial overgrowth) rather than broad, non–evidence-based panels for IEI.

    Coding

    Applicable CPT/HCPCS Procedure Codesmixed
    No codes listed
    Applicable CPT/HCPCS Procedure Codes (extended)CPT | HCPCS
    82108Aluminum.
    82127Amino acids; single, qualitative, each specimen.
    82136Amino acids, 2 to 5 amino acids, quantitative, each specimen.
    82139Amino acids, 6 or more amino acids, quantitative, each specimen.
    82300Cadmium.
    82379Carnitine (total and free), quantitative, each specimen.
    82380Carotene.
    82441Chlorinated hydrocarbons, screen.
    82495Chromium.
    82507Citrate.
    1–10 of 42
    1/5
    Procedure/CPT & HCPCS codes referencedmixed
    83655Lead
    83735Magnesium
    83785Manganese
    83885Nickel
    83918Organic acids; total, quantitative, each specimen
    83919Organic acids; qualitative, each specimen
    83921Organic acid, single, quantitative
    84134Prealbumin
    84255Selenium
    84446Tocopherol alpha (Vitamin E)
    1–10 of 19
    1/2
    inv-14: Lactose dose for adult H2 breath test — 25-50 g (adults)
    Lactose dose (adults)25–50 g of lactose for persons aged 18 and up
    Pediatric dosing noteNo consensus for children; estimates 0.5–2 g/kg up to a maximum of 25–50 g
    Pre-test preparationAvoid smoking/strenuous activity for 2 hours; avoid complex carbs and dairy for 12 hours; withhold antibiotics for 4 weeks; avoid colonic cleansers for ≥2 weeks
    Suggested test durationSuggested test time 3–5 hours; standard measuring interval for malabsorption is 30 minutes; intervals up to 60 minutes may be appropriate
    inv-15: SIBO culture threshold — >10^3 c.f.u./ml.
    SIBO culture threshold>10^3 c.f.u./ml when culture is considered for diagnosis
    Evidence qualityThreshold recommendation rated as low quality evidence by North American Expert Consensus
    Contextual noteCurrent small bowel culture techniques are considered not satisfactory for SIBO assessment; breath testing is suggested as preferred

    Provider Actions and Documentation

    Prior Authorization

    Pre-authorize IEI-directed panels when payer requires

    Prior authorization is required where the plan's coverage rules prohibit testing for IEI; laboratory panels and proprietary multi‑analyte tests used to support an IEI diagnosis do not meet coverage criteria and should be pre-authorized when the payer requires it.

    • Applies to proprietary panels and broad analyte profiling intended to confirm IEI.
    • Obtain PA consistent with member benefits if the plan restricts IEI-directed testing.
    Prior Authorization

    Verify PA for listed CPT/HCPCS codes before ordering

    Verify payer-specific prior authorization requirements when ordering any of the CPT/HCPCS procedure codes listed in the policy; these codes are associated with tests discussed in this document and may be subject to PA.

    • Examples include CPT 82108–89125, 91065 and HCPCS S3708 as listed in the policy code section.
    • Check the subscriber's benefit and any PA portal/process before ordering.
    Prior Authorization

    Follow payer PA rules for breath hydrogen/methane testing (CPT 91065)

    The document does not specify a separate prior authorization process for breath hydrogen/methane testing; when a payer requires PA, support requests for tests such as CPT 91065 with documentation of suspected bacterial overgrowth/SIBO and clinically compatible symptoms.

    • If PA is required by the member's benefits, include clinical indication for suspected SIBO and prior evaluation findings.
    Step Therapy

    Use initial noninvasive breath testing and correlate with clinical findings

    For breath testing related to suspected SIBO, consider initial noninvasive breath testing (lactulose or glucose) and interpret results together with the patient's clinical presentation before advancing to further invasive testing or specific therapy.

    • Use test results in conjunction with compatible symptoms and absence of another explanatory diagnosis.
    • Select substrate (lactulose or glucose) appropriate to the clinical question.
    Note

    Follow guideline-based indications and methods for breath testing

    Use breath hydrogen and/or methane testing selectively per guideline suggestions: test for suspected SIBO, carbohydrate maldigestion, and evaluate methane when constipation is prominent; perform fructose and lactose breath tests for at least 3 hours when indicated.

    • North American Consensus and ACG recommend breath testing for SIBO and carbohydrate maldigestion in symptomatic patients.
    • Evaluate methane excretion when associated with constipation; perform fructose/lactose breath testing for ≥3 hours as recommended.
    Note

    Provider action — local implementation / author note

    Placeholder — see policy sections on proprietary testing, breath testing, and applicable codes; author should confirm any additional payer-specific procedural requirements or local implementation notes here.

    Documentation Required

    Complete clinical evaluation (history, exam, baseline labs, exposure and symptom screening)

    Perform a focused clinical evaluation prior to ordering diagnostic testing: obtain history and physical exam, basic laboratory studies (CBC, serum electrolytes, glucose, urinalysis), occupational/environmental exposure history, and consider standardized screening questionnaires (EESI, PHQ‑9) to document symptoms and comorbidity.

    • Document symptom pattern, exposures, and psychiatric screening where appropriate.
    • Use occupational/environmental history and symptom questionnaires to support clinical indication.
    Documentation Required

    Ensure LDT validation and CLIA compliance when ordering IEI tests

    Laboratory‑developed tests (LDTs) referenced for IEI are developed and run in‑house and are regulated by CMS under CLIA as high‑complexity tests; providers ordering or using LDTs should ensure appropriate laboratory CLIA compliance and validation.

    • LDTs are not FDA‑cleared; validation and CLIA high‑complexity oversight are required.
    Documentation Required

    Document clinical indication and suspected SIBO when ordering breath testing

    Document the clinical indication supporting any test ordered under this policy (refer to the CPT/HCPCS list) and, for breath hydrogen/methane testing, specifically document suspected bacterial overgrowth (including SIBO) and compatible symptoms to meet coverage criteria.

    • Include symptom description, prior evaluations, and rationale linking testing to the clinical concern (e.g., suspected SIBO).
    • Attach relevant questionnaire results or exposure history when available.
    Denial Risk

    Claims for IEI-confirmatory tests will be denied

    Claims for laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance will be denied because such tests do not meet coverage criteria; avoid ordering tests intended solely to 'confirm' IEI for coverage purposes.

    • This includes proprietary multi‑analyte panels and broad analyte profiling when used to diagnose IEI.
    • Order only tests with a documented clinical indication consistent with policy criteria.
    Denial Risk

    Claims may be denied due to LCD/NCD precedence — verify government policies

    Claims may be denied or determined by applicable government policy (LCD/NCD) when those federal or state rules take precedence over this policy; verify Medicare/Medicaid coverage and LCD/NCD guidance for the member.

    • If a conflict exists between this policy and an applicable government policy, the government policy governs the determination.
    Denial Risk

    Claims not meeting explicit coverage criteria are denial triggers

    Claims for tests or procedures that do not meet the explicit coverage criteria in this policy may be denied; removal of the prior reimbursement section means enforcement relies on coverage criteria rather than unit‑based restrictions.

    • Ensure ordered tests clearly meet the coverage language (e.g., breath hydrogen/methane testing for suspected bacterial overgrowth).

    Background

    Idiopathic environmental intolerance (IEI) is described as a subjective syndrome of recurrent, nonspecific symptoms that patients attribute to low-level environmental exposures. The condition lacks consistent objective diagnostic findings, overlaps with common conditions such as anxiety, irritable bowel syndrome, and fibromyalgia, and frequently coexists with psychiatric comorbidity. Because symptoms and triggers are variable and subjective, standard evaluation emphasizes a careful history, physical exam, basic laboratory testing, occupational/environmental exposure history, and targeted testing only when clinically indicated rather than broad screening for IEI.

    Definitions

    inv-29: IEI — definition summary.
    DefinitionIdiopathic environmental intolerance (IEI), formerly called multiple chemical sensitivity (MCS), is a subjective condition with recurrent, nonspecific symptoms attributed to low-level chemical, biologic, or physical agents without consistent objective diagnostic findings
    Clinical featuresSymptoms are nonspecific and recurrent; overlap with conditions such as anxiety, IBS, and fibromyalgia
    Evaluation emphasisStandard evaluation emphasizes history, physical exam, basic laboratory tests, and occupational/environmental history
    inv-30: EHS / IEI-EMF — definition for electromagnetic hypersensitivity.
    DefinitionElectromagnetic hypersensitivity (EHS / IEI-EMF) is attribution of nonspecific symptoms to exposure to electromagnetic fields despite exposures below established toxicological thresholds
    Reported triggersRadiofrequencies from telecommunication devices, Wi‑Fi, base stations and other electromagnetic sources
    Evidence summarySystematic reviews and ANSES report find no consistent biological abnormalities on exposure and note possible methodological limitations or nocebo/psychological explanations
    inv-31: 1999 Consensus Document criteria for MCS/IEI — recognition criteria enumerated.
    1999 Consensus recognition criteriaChronic condition; reproducible symptoms with repeated chemical exposure; low exposure levels provoke the syndrome; removal of offending agents leads to symptom subsidence; responses occur to chemically unrelated substances
    OriginDeveloped by an international panel of 89 clinicians and researchers as the most widely used recognition criteria for MCS
    Clinical useUsed as recognition framework though condition and criteria remain controversial in medical literature
    inv-32: LDT — laboratory-developed test definition and CLIA regulation note.
    LDT definitionLaboratory‑developed tests (LDTs) are tests developed and performed in‑house by individual laboratories and are not FDA‑cleared
    Regulatory oversightLDTs are regulated by CMS under CLIA as high‑complexity tests (CLIA '88)
    Clinical implicationMany IEI-related proprietary tests are LDTs and must be validated and performed by the performing laboratory
    inv-33: IEI / MCS — syndrome definition with psychiatric comorbidity note.
    Syndrome definitionIEI/MCS describes recurrent symptoms patients attribute to low‑level chemical, electromagnetic, or other environmental exposures
    Contested pathophysiologyThe pathophysiology is contested and acceptance varies across the medical literature; expert reviews and position statements are skeptical
    Psychiatric comorbidityPsychiatric disorders are frequently comorbid and psychological assessment (eg, PHQ‑9) is often recommended during evaluation
    inv-34: SIBO — definition and note that breath hydrogen/methane testing per North American guidance is used.
    SIBO definitionSmall intestinal bacterial overgrowth (SIBO) is excessive bacteria in the small intestine that can cause bloating and other GI symptoms
    Diagnostic testingEvaluated using breath hydrogen and/or methane testing per North American Consensus and related guidelines
    Guideline notesBreath testing is suggested for SIBO and carbohydrate maldigestion; methane evaluation is recommended when associated with constipation

    References and Revision History

    The policy includes an extensive reference list supporting its positions and guidance. Citations include professional society position statements, consensus documents, guideline reviews of breath testing and SIBO, and recent clinical reviews and primary studies; the reference section lists over 30 evidence sources used to inform the coverage stance and clinical recommendations.

    2026-06-01effective_dateLatest

    Policy effective date updated to 2026-06-01.

    2025-12-03review

    Reviewed and updated background, guidelines/recommendations, and evidence-based references; clarified wording in coverage criteria including allowing breath hydrogen/methane testing for bacterial overgrowth (including SIBO); removed former reimbursement policy section; revised code descriptions for CPT 83015 and 83018 effective 2026-01-01.